Table 3.
Results of magnetic resonance imaging flowmetry in the three study groups defined according to whether or not patients received oxaliplatin-based chemotherapy and experienced sinusoidal injury
| Characteristic | All (n= 29) | No-OX (n= 8) | OX + no-SI (n= 15) | OX + SI (n= 6) | P-valuea |
|---|---|---|---|---|---|
| Portal flow, ml/s, median (IQR) | 17.9 (13.5–20.8) | 15.5 (11.0–19.1) | 19.6 (16.2–21.3) | 19.8 (14.8–23.2) | 0.241 |
| Cross-section area, cm2, median (IQR) | 1.5 (1.2–1.8) | 1.2 (0.9–1.2) | 1.7 (1.2–2.0) | 1.7 (1.6–2.1) | 0.005 |
| Mean velocity, cm/s, median (IQR) | 14.0 (12.2–16.3) | 16.3 (13.4–18.5) | 14.3 (12.7–17.4) | 12.0 (10.2–13.5) | 0.060 |
| Peak velocity, cm/s, median (IQR) | 23.2 (19.9–26.6) | 25.5 (20.3–29.3) | 24.3 (21.4–26.5) | 19.6 (18.2–26.4) | 0.311 |
a
Kruskal–Wallis test was used to compare distributions among the three groups.
No-OX, patients who did not receive oxaliplatin-based chemotherapy; OX + no-SI, patients who received oxaliplatin-based chemotherapy without sinusoidal injury; OX + SI, patients who received oxaliplatin-based chemotherapy with sinusoidal injury; IQR, interquartile range.